Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 23, Issue 11, 2016, Pages 905-911

  Martinot Peignoux, M ^a,b   Lapalus, M ^a,b   Maylin, S ^c   Boyer, N ^d   Castelnau, C ^d   Giuily, N ^d   Pouteau, M ^d   Moucari, R ^a,b   Asselah, T ^a,b,c,d   Marcellin, P ^a,b,c,d  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

HBV; nucleos(t)ide analogues; pegylated interferon alpha 2a; prognosis; serum markers

Indexed keywords

BIOLOGICAL MARKER; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; TENOFOVIR DISOPROXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; TENOFOVIR;

ADULT; ANTIGEN TITER; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS B; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; HEPATITIS B, CHRONIC; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PRECISION MEDICINE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SUSTAINED VIROLOGIC RESPONSE; TENOFOVIR; TREATMENT OUTCOME;

EID: 84993123343     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12565     Document Type: Article

References (30)

1. Lok ASF, McMahon BJ. AASLD practice guidelines update. Chronic hepatitis B: update 2009. Hepatology 2009;50:1–36.
2. Liaw YF, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statements on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561.
3. EASL clinical practice guidelines: management of chronic hepatitis B. European Association for the Study of the Liver. J Hepatol. 2012;50:227–242.
4. Lau DLTY, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2009;353:2682–2695.
5. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217.
6. Marcellin P, Bonino F, Lau GKK, et al. Sustained response of Hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009;136:2169–2179.
7. Moucari R, Korevaan A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009;50:1084–1092.
8. Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676–683.
9. Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology 2015;61:1512–1522.
10. Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial). J Hepatol. 2014;61:777–784.
11. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141–1150.
12. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151–1157.
13. Seto WK, Wong DKH, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleotside analogue therapy. Hepatology 2013;58:923–931.
14. Takkenberg RB, Jansen L, de Niet A, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon ••2a and adefovir. Antivir Ther 2013;18:895–904.
15. Tanaka E, Matsumo A, Suzuki F, et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients with low risk of lamivudine resistance. Liver Int. 2006;26:90–96.
16. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between hepatitis B virus core-related antigen and intrahepatic covalently close circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27–33.
17. Maasoumy B, Wiegand SB, Jaroszewicz J, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect. 2015;21:606e1–606e10.
18. Okuhara S, Umemura T, Joshita S, et al. Serum levels of interleukine -22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res. 2014;44:E173–E180.
19. Tanaka E, Matsumoto A. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res. 2014;44:1–8.
20. Chuaypen N, Posuwan N, Payungporn S, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Intern. 2016;36:827–836. doi: 10.1111/liv.13046.
21. van Campenhout MJH, Brouwer WP, van Oord GW, et al. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in HBeAg-positive patients. Clin Mocrobiol Infect. 2016;22:571e5–571e9. doi: 10.1016/j.cml.2016.02.002.
22. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantification can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462–1468.
23. Rijckborst V, Hansen B, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006–1011.
24. Matsumoto A, Yatsuhashi H, Nagaoka S, et al. Factors associated with the effect of interferon-a sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chroni hepatitis B. Hepatology Res. 2015;45:1195–1202. doi:10.1111/hepr.12488.
25. Nguyen T, Locarnini S. Monitoring drug therapy for hepatitis B – a global challenge. Nat Rev Gastroenterol Hepatol. 2009;6:565–567.
26. Thimme R, Dandri M. Dissecting the divergent effects of interferon –alpha on immune cells; time to rethink combination therapy in chronic hepatitis B. J Hepatol. 2013;58:205–209.
27. Marcellin M, Heathcote EJ, Buti M, et al. Tenofovir Disiproxil Fumarate versus Adefovir Dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
28. Tan AT, Hoang LT, Chin D, et al. Reduction of HBV replication prolongs the early immunological response to IFNα therapy. J Hepatol. 2014;60:54–61.
29. Marcellin P, Ahn SH, Ma X, et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134–144e10. doi: 10.1053/j.gastro.2015.09.043.
30. Biankin AV, Piantadost S, Hollingsworth S. Patients-centric trials for therapeutic development in precision oncology. Review. Nature 2015;526:361–370.